Scientific Programme & Abstracts from the International Meeting in Pediatric Endocrinology (IMPE)

impe0096fc4.2 | Growth and Syndromes | IMPE2023

Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates activity in preclinical models of FGFR3-related disorders

Muslimova Elena , Demuynck Benoit , Loisay Léa , Dambkowski Carl , Legeai-Mallet Laurence

Background: FGFR3 is a negative regulator of bone growth. Gain-of-function mutations in the FGFR3 gene result in different skeletal osteochondrodysplasias, including achondroplasia (ACH) and hypochondroplasia (HCH). ACH is the most common form of rhizomelic short stature, affecting between 1 in 15,000 and 1 in 30,000 live births worldwide. The incidence of HCH is thought to be approximately the same as ACH. Currently, there is only one approved therap...